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ABSTRACT The potential for microbes to overcome antibiotics from different classes before 25 
they reach the bacterial cells is largely unexplored. Here we show that a soluble bacterial 26 
lipocalin produced by Burkholderia cenocepacia upon exposure to sublethal antibiotic 27 
concentrations increases resistance against diverse antibiotics in vitro and in vivo. These 28 
phenotypes were recapitulated by heterologous expression in B. cenocepacia of lipocalin genes 29 
from Pseudomonas aeruginosa, Mycobacterium tuberculosis and methicillin-resistant 30 
Staphylococcus aureus. Purified lipocalin bound different classes of bactericidal antibiotics and 31 
contributed to bacterial survival in vivo. Experimental and X-ray crystal structure-guided 32 
computational studies revealed that lipocalins counteract antibiotic action by capturing 33 
antibiotics in the extracellular space. We also demonstrated that fat-soluble vitamins prevent 34 
antibiotic capture by binding bacterial lipocalin with higher affinity than antibiotics. Therefore, 35 
bacterial lipocalins contribute to antimicrobial resistance by capturing diverse antibiotics in the 36 
extracellular space at the site of infection, which can be counteracted by known vitamins. 37 
 38 
IMPORTANCE Current research on antibiotic action and resistance focuses on targeting 39 
essential functions within bacterial cells. We discovered a previously unrecognized mode of 40 
general bacterial antibiotic resistance operating in the extracellular space, which depends on 41 
bacterial protein molecules called lipocalins. These molecules are highly conserved in most 42 
bacteria and have the ability to capture different classes of antibiotics outside bacterial cells. We 43 
also discovered that liposoluble vitamins, such as vitamin E, overcome in vitro and in vivo 44 
antibiotic resistance mediated by bacterial lipocalins, providing an unexpected new alternative to 45 
combat resistance by using this vitamin or its derivatives as antibiotic adjuvants.  46 
  47 
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Treating infections is becoming increasingly difficult since microbes often show intrinsic, high-48 
level resistance to virtually all clinically approved antibiotics (1). Ineffective microbial killing 49 
and exposure to sublethal antibiotic concentrations elicit adaptive bacterial stress responses 50 
enhancing antibiotic resistance and tolerance (2-7). Much has been learned about antibiotic 51 
resistance mechanisms at the cellular level (8, 9), but whether microbes subvert the action of 52 
antibiotics before they come in contact with the bacterial cells has remained largely unexplored 53 
with the exception of β-lactamases, which are often trapped into released membrane vesicles (10-54 
13). 55 
 Burkholderia cenocepacia is a highly multidrug resistant, opportunistic Gram-negative 56 
bacterium that causes serious respiratory infections in patients with cystic fibrosis (14). Bacteria 57 
of the genus Burkholderia are notorious for their ability to resist the action of multiple classes of 58 
antimicrobials (15), representing an attractive model to understand intrinsic mechanisms of 59 
resistance in opportunistic bacteria. Recently, we showed that in response to sublethal antibiotic 60 
concentrations, B. cenocepacia produce and release molecules such as the polyamine putrescine 61 
and YceI, a conserved hypothetical protein of unknown function (16). YceI proteins comprise a 62 
family of bacterial lipocalins (herein abbreviated as BCNs), which are small proteins widely 63 
conserved in Gram-negative and Gram-positive bacteria, but whose physiological role is unclear 64 
(17, 18). In co-culture experiments, B. cenocepacia protects Pseudomonas aeruginosa from 65 
killing by different bactericidal antibiotics (16). This effect was abrogated in the B. cenocepacia 66 
double deletion mutant ΔbcnA-bcnB (16), but the individual contribution of each BCN paralog 67 
and their mechanisms remained unknown.  68 
 Here, we show that secreted BcnA contributes to increased resistance of B. cenocepacia to 69 
various classes of antibiotics in vitro and in vivo. The expression of BCN orthologs from P. 70 
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aeruginosa, Mycobacterium tuberculosis and methicillin-resistant Staphylococcus aureus in B. 71 
cenocepacia ΔbcnA recapitulated this function. Experimental and computational studies revealed 72 
that BCNs bind to a range of antibiotics, thus preventing their antibacterial activity and 73 
contributing to resistance. X-ray crystallography studies of BCN structures, in combination with 74 
docking and MD simulations, have helped us to rationalize plausible binding modes. We also 75 
discovered that fat-soluble vitamins bound BcnA with a higher affinity than antibiotics, enabling 76 
them to outcompete antibiotics. This finding provides a clinically applicable strategy whereby 77 
known vitamins could become antibiotic adjuvants by increasing the concentration of free 78 
antibiotics in the proximity of bacterial cells, thereby boosting their microbicidal activity. 79 
 80 
RESULTS 81 
 82 
BcnA is a secreted bacterial lipocalin required for full resistance of B. cenocepacia to 83 
different classes of antibiotics. We investigated the role of B. cenocepacia BcnA (BCAL3311) 84 
and BcnB (BCAL3310) by constructing individual deletion mutants in their corresponding genes 85 
and assessing bacterial susceptibility to model bactericidal antibiotics representing different 86 
classes including rifamycins (mRNA transcription inhibitors), fluoroquinolones (DNA 87 
replication inhibitors), several β-lactams (cell wall peptidoglycan synthesis inhibitors), and 88 
cationic antimicrobial peptides (cell membrane active agents). The ∆bcnA mutant, but not 89 
∆bcnB, had increased susceptibility (4-fold MIC reduction) to rifampicin, norfloxacin, 90 
ceftazidime, and the cationic antimicrobial peptide polymyxin B (PmB), and 2-fold MIC 91 
reduction to meropenem. No effect was observed with the aminoglycoside gentamicin (protein 92 
synthesis inhibitor) (Fig. 1A; see antibiotic chemical structures in Fig. S1). Similarly, we also 93 
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tested model bacteriostatic antibiotics representing different classes. The ∆bcnA mutant, but not 94 
∆bcnB, had increased susceptibility to minocycline (tetracycline family protein synthesis 95 
inhibitor; 4-fold MIC reduction), and trimethoprim (pyrimidine inhibitor of bacterial 96 
dihydrofolate reductase; 2-fold MIC reduction), while no effect was observed with the macrolide 97 
(protein synthesis inhibitor) azithromycin (Fig. 1A and Fig. S1).  98 
 The expression of bcnA and bcnB genes in response to antibiotics at near-MIC (sublethal) 99 
concentrations was characterized by constructing chromosomal lux fusions. Expression of 100 
bcnA::luxCDABE was upregulated upon exposure to PmB, rifampicin, and norfloxacin, but not 101 
ceftazidime (Fig. 1B). In contrast, bcnA::luxCDABE expression was slightly reduced in response 102 
to gentamicin, likely due to protein synthesis inhibition at near-MIC concentrations (Fig. 1B). 103 
Expression of bcnB::luxCDABE only increased by exposure to norfloxacin and ceftazidime, and 104 
was slightly reduced by rifampicin and gentamicin (Fig. S2A). Thus, bcnA and bcnB genes 105 
respond to antibiotic stress, but they appeared to be differentially regulated. bcnA and bcnB are 106 
located on the same strand and apart by 63 base pairs (Fig. 1C). Immediately upstream of bcnA 107 
there is an open reading frame (BCAL3312), also transcribed in the same strand, which encodes 108 
a predicted cytochrome b651 protein. Putative promoter regions are found upstream from 109 
BCA3312 and downstream from bcnB next to a predicted Rho-independent transcription 110 
termination sequence. The genomic organization of the bcn region suggest BCAL3312-bcnA-111 
bcnB are cotranscribed and may form an operon. However, the transcribed 63-bp intergenetic 112 
region between bcnA and bcnB has the potential to form strong RNA secondary structures, which 113 
might explain the differential regulation of both genes by antibiotics. The secretion of BcnA and 114 
BcnB proteins was also investigated using FLAG-tagged derivatives; only BcnA was secreted 115 
extracellularly into the growth medium (Fig. S2B). From these experiments, we concluded that 116 
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BcnA is the major contributor to intrinsic antibiotic resistance upon antibiotic stress and is 117 
secreted to the extracellular bacterial milieu. 118 
 BCN orthologs from different species restore BcnA function in B. cenocepacia. To 119 
demonstrate whether BCN orthologs from other bacteria could restore BcnA function in the 120 
∆bcnA strain, we tested BCNs of P. aeruginosa PAO1 [PA0423, PA4340 and PA4345, herein 121 
BcnA1(Pa), 2 (Pa), and 3(Pa), respectively], Mycobacterium tuberculosis H37Rv [Rv1890c, 122 
BcnA(MTb)] and the community-acquired methicillin-resistant Staphylococcus aureus USA300 123 
[SAUSA300_2620, BcnA(Sa)]. CFU counts on PmB-containing plates (Fig. 2A), and Etest 124 
MICs against rifampicin, ceftazidime, and ciprofloxacin (a fluoroquinolone closely related to 125 
norfloxacin) (Fig. 2B) showed that heterologous expression of BCNs from these different 126 
bacteria restores antibiotic resistance to parental levels, indicating these proteins have a 127 
conserved function. 128 
 BcnA sequesters antibiotics. BCNs bind to diverse hydrophobic molecules (19-21); hence 129 
we hypothesized that BCNs could capture antibiotics and reduce their effective concentration in 130 
the bacterial milieu. An antibiotic bioassay demonstrated that BcnA sequestered rifampicin, 131 
PmB, norfloxacin and ceftazidime, in descending order of magnitude, but not gentamicin (Fig. 132 
3A and Fig. S3, A-E). Further, the relative affinity of BcnA for antibiotics was determined in 133 
vitro by binding competition of antibiotics with Nile Red in complex with BcnA. Nile Red is a 134 
fluorophore used to test hydrophobic binding sites in proteins (22). The calculated binding 135 
inhibitory constants (Ki values) for each antibiotic (Fig. 3B and Fig. S3, F-M) mirrored their 136 
relative ability to be sequestered by BcnA (Fig. 3A) and the antibiotic susceptibility phenotypes 137 
of ∆bcnA (Fig. 1A). Notably, the binding of BcnB to Nile Red occurred at ~20-fold lower 138 
affinity than that of BcnA (Fig. S3, N-Q) agreeing with the lesser role of BcnB in antibiotic 139 
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resistance. The involvement of hydrophobic moieties in the interaction of ligands with BcnA was 140 
suggested by the significantly higher Ki value of PmB nonapeptide, which lacks the hydrophobic 141 
N-terminal tail of PmB (23), relative to PmB (Fig. 3B, Fig. S3, F-I). Notably, azithromycin and 142 
gentamicin, the only antibiotics not showing antibiotic sensitivity reduction phenotype with 143 
ΔbcnA (Fig. 1A), are the only tested antibiotics lacking aromatic or hydrophobic moieties (Fig. 144 
S1). To test polar hydrophilic binding sites in BcnA compared to hydrophobic sites, we used two 145 
related BODIPY dye-labelled phospholipids. BcnA increased the intensity of fluorescence of 146 
BODIPY fluorophore when attached to fatty acyl chain of the phospholipid in BODIPY-147 
phosphocholine, but not when attached to the hydrophilic polar head group (BODIPY-148 
phosphoethanolamine) (Fig. S3, R-T). This further supported a role for fatty acyl chains in the 149 
interaction with hydrophobic sites in BcnA. 150 
 Structure and molecular modeling reveal distinct docked binding modes for BcnA. To 151 
elucidate the mode of binding of antibiotics within BCNs, we first solved the X-ray crystal 152 
structures of BcnA and BcnB to 1.4- and 1.6-Å resolution, respectively (Supplemental Results, 153 
Table S1 and Fig S4A-E). Visual inspection and structural alignments by the DALI server (24) 154 
confirmed a barrel-shaped lipocalin fold for both proteins (Fig. 4A and B). An octaprenyl 155 
pyrophosphate was bound within a long, hydrophobic tunnel extending from one end of the 156 
barrel in each structure (Fig. S4A and B). The binding of octaprenyl pyrophosphate potentially 157 
occurred during recombinant expression in Escherichia coli. Analysis with the PDBePISA server 158 
(25) predicted that BcnA is a monomer whilst  BcnB is a dimer by crystallographic symmetry 159 
(~2840 Å2 of buried surface area including a portion of the tunnel opening). These oligomeric 160 
states were confirmed in solution using size exclusion chromatography-multiangle light 161 
scattering (SEC-MALS, Fig. S4C and D). Superposition of BcnA chain A and BcnB chain C 162 
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(148 Cα atoms, 22% sequence identity) resulted in a root mean squared deviation of 1.66 Å (Fig. 163 
4C). The largest structural differences observed were located in two of the loops that make up 164 
the tunnel opening (Fig. 4C). These differences may play a role in the antibiotic binding potential 165 
of BcnA and BcnB.  166 
 Using the established crystallographic structures, we applied molecular modeling and 167 
docking calculations to predict BCN binding modes for antibiotics (Supplemental Results). These 168 
studies suggested two distinct docked binding modes for BcnA. One binding mode involved 169 
residues in the rim of the lipocalin pocket (Fig. 4D and Fig. S4F-I). Polar interactions, mainly 170 
with polar residues, were observed with all tested antibiotics. There were also interactions 171 
between the aromatic moieties in PmB, rifampicin, norfloxacin, and ceftazidime, and lipophilic 172 
residues. These interactions were not observed with gentamicin, as it lacks aromatic moieties; 173 
that may contribute to weak binding to BcnA. The second binding mode was predicted for more 174 
lipophilic molecules (e.g. Nile Red), occurring deeper inside the lipophilic tunnel (Fig. 4E). 175 
Further, analyses from molecular dynamics (MD) simulations suggested both structural and 176 
ligand recognition roles for residues D82 and D93 (Supplemental Results). These residues are 177 
located in the loops at the top of the tunnel opening of BcnA. Site-directed mutagenesis was 178 
performed and the BcnAD82A-D93A mutant showed decreased binding affinity for Nile Red (Fig. 179 
S5A-B), which we propose is due to structural changes (Supplemental Results, Fig. S6A-E, and 180 
Fig. S7). Docking Nile Red into the BcnAD82A-D93A mutant (following the general docking 181 
protocol with the minimized average structure from the ns 2.5 to the ns 5 of the MD simulation) 182 
did not lead to any binding position inside the lipophilic tunnel (Fig. S7). Interestingly, D93 is a 183 
highly conserved residue in the consensus motif of the BCN protein family (Fig. S5C), 184 
exemplified in the alignment of BCN homologs (Fig. S5D). Further, Asp is found in equivalent 185 
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positions to D82 in homologs of B. cenocepacia BcnA. Thus, it is credible that the mode of 186 
interaction between BcnA and antibiotics is common among this large family of conserved 187 
bacterial proteins. 188 
 Exogenous BcnA protects different bacterial species from antibiotic killing in vitro and 189 
in vivo. Since B. cenocepacia BcnA is secreted (Fig. S2D), as predicted for most other BCNs, we 190 
therefore hypothesized that exogenous BCNs produced by one bacterial species have the 191 
potential to protect other bacteria from the action of antibiotics including antimicrobial peptides. 192 
This was investigated using purified recombinant BCNs from B. cenocepacia.  In vitro antibiotic 193 
protection assays showed that P. aeruginosa PAO1 treated with 1.5 µM purified BcnA had 194 
reduced sensitivity to PmB, but not with BcnB (Fig. 5A). In contrast, at 8- to 16-fold lower PmB 195 
concentrations, both proteins protected Salmonella enterica Typhi, Shigella flexneri, 196 
Acinetobacter baumannii, Acinetobacter lwoffii, and Acinetobacter junii strains (Fig. S7A). This 197 
disparity in the PmB concentrations at which protection by BcnA and BcnB occurs correlates 198 
with their relative affinities to Nile red (Fig. S3N-Q, see above). In vivo infections in C57BL/6 199 
mice demonstrated that BcnA protected P. aeruginosa Q502, a virulent cystic fibrosis clinical 200 
isolate (26), from PmB killing in an intraperitoneal sepsis model (Fig. 5B). We also employed 201 
the Galleria mellonella larvae infection model. The ∆bcnA and ∆bcnB mutants had reduced 202 
virulence in G. mellonella relative to the parent strain (Fig. S7B). However, significantly lower 203 
numbers of ∆bcnA bacteria than parental and ∆bcnB strains were recovered from the hemolymph 204 
of infected larvae at 200 min post-infection (Fig. S6B), suggesting ∆bcnA bacteria were more 205 
susceptible than ∆bcnB to larvae's humoral immune response, which is mainly driven by host 206 
antimicrobial peptides (27, 28), mirroring the different in vitro susceptibility of ∆bcnA and 207 
∆bcnB to PmB. Similarly, infection of BcnA-treated Galleria mellonella larvae with P. 208 
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aeruginosa PAO1, resulted in more rapid killing of the larvae than control or BcnB-treated 209 
larvae (Fig. 5C). We recovered significantly higher bacterial CFUs from the hemolymph of 210 
BcnA-treated infected larvae (Fig. 5D), suggesting that exogenous BcnA provides a survival 211 
advantage to infecting bacteria. Enhanced bacterial killing of BcnA-treated larvae was also 212 
observed for Klebsiella pneumonia, A. baumannii, and S. aureus USA300 (Fig. S7C). Together, 213 
the in vivo infections results underpin a biological role for BCNs in providing a survival 214 
advantage to infecting bacteria from different species. 215 
 Liposoluble vitamins inhibit BcnA-mediated antibiotic capture. Conceivably, molecules 216 
with superior binding affinity to BCNs than that of antibiotics should prevent BCN mediated 217 
resistance. Since lipophilic moieties are predicted to bind deep within the BCN pocket, we tested 218 
normal dietary hydrophobic supplements, recommended for several patient groups including 219 
cystic fibrosis patients, such as the fat-soluble vitamins α-tocopherol (vitamin E) and 220 
menaquinone (vitamin K2). Docking of α-tocopherol showed its alkyl chain buried into the 221 
BcnA tunnel and its cyclic head placed towards the entrance, similar to the Nile Red binding 222 
pose (Fig. 4E). Of note, α-tocopherol followed by menaquinone exhibited very low Ki values in 223 
Nile Red displacement assays (~2-4 orders of magnitude lower than the Ki values of antibiotics), 224 
indicative of their high affinity to BcnA (Fig. 3B). This prompted us to test the BCN-inhibitory 225 
activity of fat-soluble vitamins in vivo. Using G. mellonella larvae infected with P. aeruginosa 226 
PAO1, 10 µM of either α-tocopherol or menaquinone significantly reduced the survival 227 
advantage of P. aeruginosa in BcnA-treated larvae (Fig. 6A). This supports the notion that the 228 
protective function of BCN on infecting bacteria can be inhibited in vivo (Fig. 6B). 229 
 230 
DISCUSSION 231 
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Lipocalins are an ancient family of small proteins found in all kingdoms of life with the ability to 232 
bind hydrophobic ligands, but with different functions depending on the cell types and organisms 233 
(29, 30). In many cases and particularly in bacteria (17), their function is unclear although BCN 234 
orthologs can be found by data mining in the majority of completed genomes. In this study, we 235 
have demonstrated for the first time that secreted BCNs contribute to antibiotic resistance by 236 
capturing and neutralizing antibiotics in the bacterial milieu. BCNs bind a range of antibiotics 237 
with diverse chemical structures, increasing antibiotic resistance in vitro and enhancing bacterial 238 
survival in vivo. Our structural work suggests that BCNs have two binding modes. Hydrophobic 239 
molecules like Nile Red and Vitamin E and K2 can bind in the interior of the lipocalin tunnel, 240 
while antibiotic molecules interact with the rim and their binding properties are much weaker. 241 
This suggests that antibiotic binding and scavenging is not a primary function of secreted BCNs 242 
but these proteins may also have other yet undiscovered roles. 243 
 We propose that the antibiotic binding ability of BCNs becomes particularly relevant under 244 
conditions whereby antibiotics cannot effectively kill bacteria and their presence in sublethal 245 
concentrations elicits protective bacterial stress responses. Exposure to antibiotics triggers 246 
complex and multi-factorial bacterial processes involving changes in regulation, metabolism and 247 
energy generation (31-35). There is a body of evidence indicating that antibiotics at sublethal 248 
concentrations can stimulate the production of reactive oxygen intermediates (36-40), and also 249 
that oxidative stress associated with pathological inflammation reduces the efficacy of antibiotics 250 
(33). The increased bcnA transcription upon antibiotic treatment indicates this gene responds to 251 
antibiotic-induced stress. Recent work in the model plant Arabidopsis thaliana shows that two 252 
lipocalins that are related to bacterial orthologs have distinct but overlapping functions essential 253 
for protection from lipid peroxidation (41). Further, the mammalian odorant-binding protein, a 254 
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soluble lipocalin, protected the bacterial cells from hydrogen peroxide-induced stress when 255 
overexpressed in E. coli (42), whereas P. aeruginosa PAO1 BcnA1(Pa) was overexpressed in 256 
response to hydrogen peroxide and paraquat (43). Donnarumma et al. (18) have recently 257 
suggested that the highly conserved Neisseria BCN (GNA1030) is a ubiquinone-8 binding 258 
protein. Since ubiquinone-8 is a cofactor mainly involved in the electron transport chain (44) and 259 
with antioxidant properties(45), these authors propose a role for this protein in antioxidant 260 
defense, perhaps by delivering ubiquinone-8 to the bacterial membrane or the periplasmic space. 261 
Ubiquinones are prenylated benzoquinones. Interestingly, the majority of known crystal 262 
structures of bacterial lipocalins including BcnA and BcnB have been solved with octaprenyl-263 
like molecules bound to the lipocalin tunnel, although it is not certain if the presence of this 264 
molecule corresponds to a physiological substrate or is an artefact associated with the protein 265 
purification prior to crystallization. Therefore, while it may be reasonable to propose that BCNs 266 
could play a role in oxidative stress responses the mechanisms involved remain to be elucidated. 267 
 In summary, we have uncovered a new bacterial strategy for general antibiotic resistance 268 
operating extracellularly based on BCN-mediated antibiotic capture, which provide bacteria with 269 
a selective advantage to overcome antibiotic toxicity particularly in chronic infections where 270 
antibiotic treatment often fails. Further, we reveal a strategy to disrupt antibiotic capture and 271 
propose liposoluble vitamins as clinically usable BCN inhibitors. 272 
 273 
MATERIAL AND METHODS 274 
Strains and reagents. Table S2 lists bacteria and plasmids used in this study. Bacteria were 275 
grown in LB (supplemented with 0.4% rhamnose when required) at 37°C. Escherichia coli 276 
cultures were supplemented as required with the following antibiotics (final concentrations): 277 
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tetracycline (30 µg/ml), kanamycin (40 µg/ml), and trimethoprim (50 µg/ml). B. cenocepacia 278 
cultures were supplemented as required with trimethoprim (100 µg/ml), and tetracycline (100 279 
µg/ml). Antibiotics (Sigma) were diluted in water except for PmB, which was diluted in 0.2% 280 
bovine serum albumin/0.01% glacial acetic acid buffer. Rifampicin was dissolved in dimethyl 281 
sulfoxide (DMSO). 282 
 General molecular techniques. DNA manipulations were performed as previously 283 
described (46). T4 DNA ligase (Roche Diagnostics), Antarctic phosphatase (New England 284 
Biolabs) and restriction endonucleases were used as recommended by the manufacturers. 285 
Transformation of E. coli GT115 and DH5α was performed using the calcium chloride method 286 
(47). Mobilization of plasmids into B. cenocepacia was conducted by triparental mating (48)  287 
using E. coli DH5α carrying the helper plasmid pRK2013 (49). DNA amplification by 288 
polymerase chain reaction (PCR) was performed using a C1000 Thermal cycler (Bio-Rad 289 
Laboratories Ltd., Mississauga, Ontario, Canada) with Taq or HotStar HiFidelity DNA 290 
polymerases (Qiagen) and optimized for each primer pair. DNA sequencing was carried out at 291 
Eurofins, Huntsville, Alabama, USA. The DNA sequences were analyzed with the BLAST 292 
computer program and compared to the sequenced genome of B. cenocepacia strain J2315. The 293 
sequence of S. aureus gene SAUSA300_2620 was optimized for B. cenocepacia codon usage 294 
and custom synthesized at Eurofins. Cloning, expression, and purification of bacteriocalins was 295 
performed as previously described (16). Transcriptional fusions to luxCDABE and the 296 
subsequent luminescence expression assays were performed as previously described (36). For 297 
site-directed mutagenesis, pOE16 was amplified with Pfu polymerase using the appropriate 298 
primer pairs; the PCR products were digested overnight with 1 U DpnI at 37°C, and then 299 
introduced into E. coli DH5α competent cells by transformation. Transformants were selected on 300 
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LB agar plates supplemented with kanamycin; amino-acid replacements were confirmed by 301 
DNA sequencing. 302 
 Protein analysis and Western Blotting. Overnight cultures were diluted to OD600 0.03 in 30 303 
ml fresh LB medium with or without PmB and incubated for 3.5 h at 37oC, 200 rpm. Following 304 
incubation, cells equivalent to OD600 ~0.2 were pelleted, resuspended in 30 µl SDS-PAGE 305 
protein loading dye, and boiled to obtain whole cell lysates. Secreted proteins were precipitated 306 
from the supernatant of the rest of the cultures using 10% trichloroacetic acid as previously 307 
described (50). Precipitated proteins were resuspended in Tris buffer, 1 M, pH 7.5. The volume 308 
of protein samples loaded to the 16% SDS-polyacrylamide gel was normalized to the OD600 309 
value. After SDS–PAGE, proteins were transferred onto nitrocellulose membranes and the 310 
membranes were blocked overnight at 4°C with Western blocking reagent (Roche Diagnostics, 311 
Laval, QC, Canada) in TBST (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1 % Tween-20). The 312 
primary antibodies, anti-FLAG M2 monoclonal antibody (Sigma) or anti-α-subunit RNA 313 
Polymerase (E. coli) (Neoclone, Madison, WI, USA), were diluted to 1:15,000 in TBST and 314 
applied for 1.5 h. Secondary antibody, goat anti-mouse Alexa Fluor 680 IgG antibodies 315 
(Invitrogen), was diluted to 1:15,000 and applied for 1 h. Western blots were developed using 316 
LI-COR Odyssey infrared imaging system (LI-COR Biosciences, Lincoln, NE, USA). 317 
 Antibiotic susceptibility testing. The inoculum of B. cenocepacia K56-2, the appropriate 318 
mutants and other bacterial species was prepared by the direct colony suspension method 319 
according to CLSI (51). Cultures of OD600 of 0.0008 in fresh cation-adjusted MHB with or 320 
without the antibiotic were incubated at 37°C with medium continuous shaking in a Bioscreen C 321 
automated growth curve analyzer (MTX Lab Systems, Vienna, VA, USA). Bacterial growth was 322 
assessed turbidimetrically at 600 nm. Etest strips (AB bioMérieux, Solna, Sweden) were applied 323 
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to agar plates (17 ml agar in 85 mm Petri dish) inoculated with test bacteria by swabbing 324 
overnight cultures diluted to OD600 of 0.04; plates were then incubated at 37oC for 24 h. 325 
Alternatively, population analysis profiling (PAP) was performed turbidimetrically or by cfu 326 
counting as previously described (16). For in vitro protection assays, B. cenocepacia 327 
bacteriocalins were added to LB broth at a final concentration of 1.5 µM. 328 
 In vitro binding assays. These assays were performed as previously described (22) with few 329 
modifications. Purified BCNs were prepared in phosphate buffered saline (PBS, pH 7.4). 330 
Phospholipids and Nile Red were prepared in DMSO. The binding of each fluorescent probe to 331 
BCNs was measured by titrating 100 µl of BCNs (1.5 µM) in a flat bottom 96-well microtiter 332 
plate (LUMITRAC 200 White, Greiner bio-one, Monroe, NC, USA) with aliquots of increasing 333 
concentrations of probe until fluorescence intensity reached plateau indicating all binding sites 334 
were occupied. All spectra were corrected for background fluorescence determined from probe 335 
into buffer titrations. Fluorescence was measured using a Cary Eclipse Fluorescence 336 
spectrophotometer (Varian) set at an excitation wavelength (λex) specific for each probe, as 337 
follows: Nile Red (550 nm), and BODIPY phospholipids (500 nm for fatty acyl BODIPY labeled 338 
phosphocholine and 505 nm for head group BODIPY labeled phosphoethanolamine). The 339 
emission spectrum for each probe was collected across the following wavelengths (λem): Nile 340 
Red (590–750 nm), and BODIPY phospholipids (510–665 nm). The background-corrected 341 
binding fluorescence with each probe was fitted to a one-site binding model as previously 342 
described for human AGP (22). The equilibrium binding affinity constant for the probe–BCN 343 
complex (KD), the probe concentration needed to achieve a half-maximum binding at 344 
equilibrium, was determined by non-linear least square regression analysis of the binding 345 
isotherms using GraphPad Prism V5.0 software (GraphPad software). 346 
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 For probe displacement experiments, antibiotic solutions and fat-soluble vitamins (prepared 347 
in DMSO) diluted in PBS, pH 7.4 were titrated against BCN–probe complex at a saturating 348 
concentration necessary to obtain the maximum fluorescence when bound. Displacement of 349 
probe was measured as the corresponding decrease in fluorescence upon the progressive increase 350 
of antibiotic concentration. The binding inhibitory constants (Ki) for the test compounds were 351 
determined by nonlinear regression analysis using competition-binding equations for one site 352 
binding calculated by GraphPad Prism V5.0 software. The lower the Ki values, the higher the 353 
affinity of the molecule to BcnA. All fluorometric assays were conducted in duplicate 3 354 
independent times. 355 
 Galleria mellonella larvae in vivo infection. These assays were performed as described (52) 356 
with modifications. Overnight cultures were diluted in PBS, pH 7.4 with or without B. 357 
cenocepacia BCNs at 1.5 µM final concentration to OD600 as follows: B. cenocepacia and P. 358 
aeruginosa PAO1 to 0.00004, K. pneumoniae Kpn18 to 0.04, A. baumannii AB1 to 0.4 and S. 359 
aureus USA300 to 0.004. The larvae were injected with 10 µl of the bacterial suspensions or 360 
sterile PBS (10 larvae/group in each experiment) using 10 µl Microliter syringes (Hamilton). The 361 
larvae were incubated at 30oC and their viability was checked at regular time intervals. In similar 362 
assays, 5 larvae/group were sacrificed at 200 min post-infection and the hemolymph was 363 
extracted as previously described (52). The hemolymph was immediately serially diluted in PBS, 364 
plated on LB agar supplemented with 0.3% cetrimide or 200 µg/ml Ampicillin- 25 µg/ml PmB to 365 
quantify the cfu of P. aeruginosa PAO1 or B. cenocepacia respectively recovered from the 366 
infected larvae. 367 
 368 
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 Intraperitoneal infection in mice. A clinical isolate of Pseudomonas aeruginosa (strain 369 
Q502) was grown overnight in nutrient broth at 37°C with constant agitation. The bacteria were 370 
centrifuged at 2000 ×g and washed 3 times in sterile endotoxin-free PBS. The bacteria were 371 
resuspended in sterile injection-grade saline and the inoculum adjusted to an optical density of 372 
0.5 (A550). Female, adult (8-12-week old) C57BL6 mice were infected intraperitoneally with 100 373 
μl of the bacterial suspension, subsequent growth of the inoculum on nutrient agar demonstrated 374 
that each animal received 106 CFU. A sample size of n=6 mice per treatment was used. This was 375 
determined by GraphPad StatMate 2.0 to ensure 80% power to detect statistically significant 376 
effects between antibiotic treated and untreated animals at significance level (alpha) of 0.05, 377 
two-tailed. The actual power was >99%. Mice were selected at random from open stock cages (n 378 
= 10 per cage), ear marked to allow individual identification and then sequentially placed into 379 
treatment groups. During the course of the experiment mice were housed in individually 380 
ventilated cages “IVCs”.  This method of assigning animals to groups ensures that there is 381 
approximately equal distribution of mice from different stock cages in each group to minimize 382 
the influence of cage-to-cage variability. At the time of inoculation, the mice were treated with 383 
PmB at the standard pediatric dose of 20,000U/kg (n = 6), PmB and 100 µl of 25 µM BCN (n = 384 
6), BCN only (n = 6), or a saline control (n = 6) by intraperitoneal injection. The individual 385 
components injected into mice were added to the same syringe immediately before the IP 386 
injection. Animals were culled by cervical dislocation 4 h post inoculation. The time point was 387 
selected since by this time point and under the infection conditions the untreated mice reach the 388 
humane end point and need to be culled, as defined within the UK Home Office license under 389 
which the experiments were carried out (PLL 2700).  Due to the virulence of the clinical isolate, 390 
the dose of the bacterial inoculum, and because the bacteria are delivered IP, the mice rapidly 391 
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succumb to the infection.  In contrast, those given effective antibiotic treatment rapidly clear the 392 
infection and remain perfectly healthy.  The vast divergence in response seen in this model 393 
provides us with the statistical power to robustly assess the microbial response to antibiotic 394 
therapies without requiring the use of a very large numbers of mice per group.  We are therefore, 395 
adhering to the reduction principle of the 3Rs. The peritoneal cavity was lavaged with 3.5 mL of 396 
ice-cold sterile endotoxin free PBS and the volume recovered recorded. Serial dilutions of the 397 
lavage fluid were plated onto cetrimide agar; bacterial colonies were counted after 24 hours of 398 
growth at 37°C. Harvesting the samples and quantifying the bacterial burden in the mice was 399 
blinded to the treatment groups. Data were not normally distributed and there was not equal 400 
variance between groups; therefore, a non-parametric Kruskal-Wallis test was used. Mouse 401 
infection experiments carried out were assessed by the Queen’s University Belfast animal 402 
welfare and ethical review body (AWERB) committee and conducted under a license issued by 403 
the UK home office under the Animals (scientific procedures) Act 1986, amended 2012. 404 
 Antibiotic bioassay. Antibiotic test solutions with or without 1.5 µM BcnA were incubated 405 
for 30 min at 37oC with rotation. The solutions were filtered through filter units with MWCO 10 406 
KDa by centrifugation at 7500g, at 4oC for 10 min. The concentration of antibiotics in the 407 
filtrates was determined by spotting 5 µl on sterile filter discs placed on agar plates swabbed 408 
with the test bacteria. Petri dishes (15 cm diameter) containing 40 ml LB agar were swabbed 409 
with bacterial suspensions of OD600 0.04.  The plates were incubated at 37oC for 24 hr. Each 410 
plate included 4 discs containing standard concentrations of the antibiotic alongside the discs 411 
impregnated with test and control antibiotic solutions. E. coli DH5α was used for bioassays of 412 
PmB, norfloxacin, ceftazidime and gentamicin and S. aureus USA300 for bioassays of 413 
rifampicin. The theoretical disc content of the test antibiotic solutions was 10, 5, 2, 30 and 10 µg 414 
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for PmB, rifampicin, norfloxacin, ceftazidime and gentamicin respectively. Standard antibiotic 415 
discs contained 2-fold higher, the same amount, 2 and 4-fold lower than the test antibiotic discs. 416 
After incubation, the clear zones of inhibition were measured and the antibiotic concentrations 417 
were determined from standard curves constructed from the standard antibiotic discs. 418 
 Structure determination. BcnA and BcnB was purified by FPLC and concentrated to ~ 20 419 
mg/ml in 20 mM Tris, pH 7.5, 100 mM NaCl (1% DMSO for BcnB) with > 95% purity. Protein 420 
solutions were mixed 1:1 with mother liquor and crystals were grown at room temperature. 421 
BcnA crystals grew with 0.1 M Tris, pH 8.5 and 2.4 M ammonium sulphate (final pH 8.0) as the 422 
mother liquor. BcnB crystals grew with 0.1 M HEPES pH 6.5, 26% PEG 6000 as the mother 423 
liquor. Datasets were collected on beam line 08ID-1 at the Canadian Light Source (53), 424 
integrated using iMOSFLM (54), and scaled with AIMLESS (55) from CCP4. Phases for BcnA 425 
and BcnB were obtained using Phaser.MRage (56) from PHENIX using PDB ID 2FGS and 426 
1WUB, respectively, as the search models. Both structures were initially built with AutoBuild 427 
(57) from PHENIX, and then manually built with Coot (58). The BcnA and BcnB structures 428 
were refined with phenix.refine (59) from PHENIX and REFMAC5 (60) from CCP4, 429 
respectively, with TLS refinement for both. Figures were generated using Pymol, version 1.8 430 
(https://www.pymol.org/). Data collection and refinement statistics are provided in Extended 431 
Data Table 1. Size exclusion chromatography-multiangle light scattering (SEC-MALS) 432 
experiments were conducted to assess the oligomeric solution state of BcnA and BcnB as 433 
previously described (61) with proteins diluted to 1 mg/ml in 20 mM Tris, pH 7.5, 100 mM 434 
NaCl.  435 
 436 
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 Computational Methods. All codes can be obtained under License Agreement: AMBER 12 437 
and Amber Tools (www.ambermd.org), Maestro suite (www.schrodinger.com), AutoDock 4.2.2 438 
and AutoDockTools (http://autodock.scripps.edu, free software). Amber and Maestro have 439 
Academic fees. We studied the stability of the two X-ray structures for BcnA and BcnB, as well 440 
as the D82A-D93A mutant by molecular dynamic (MD) simulations as implemented in AMBER 441 
12. The initial model of D82A-D93A was built with Amber Tools. Missing hydrogen atoms were 442 
added and protonation state of ionizable groups was computed by using Maestro Protein 443 
Preparation Wizard, version 9.3 (https://www.schrodinger.com/maestro). Atom types and 444 
charges were assigned according to AMBER ff10 force field (62). The three molecular systems 445 
were hydrated by using cubic boxes containing explicit TIP3P water molecules extending 10 Å 446 
away from any protein atom for simulating the aqueous environment with the help of Amber 447 
Tools with added counter ions to neutralize the system. Before the MD simulations, the two 448 
systems were equilibrated under the following protocol: initial 8000 steps of steepest descent 449 
minimization, followed by heating of the system with position restrain (force constant of 20 kcal 450 
mol-1 Å-2) for all protein atoms during 10 ps of MD simulation increasing the temperature from 451 
100 K to 300 K plus additional 15 ps at constant temperature of 300 K. Position restrain was 452 
gradually decreased during 100 ps at constant 300 K, until the full system was under no restrains 453 
with constant temperature (300 K) and pressure (1 atm). After equilibration, 20 ns of MD 454 
simulation were run at constant temperature (300 K) and pressure (1 atm). Short and long-range 455 
forces were calculated every one and two time steps, respectively (each time step = 2.0 fs), 456 
constraining the covalent bonds involving hydrogen atoms to their equilibrium values. Long-457 
range electrostatic interactions were accounted for by means of the particle mesh Ewald 458 
approach applying periodic boundary conditions. The root mean square deviation (RMSD) as a 459 
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function of time with respect to the starting structure for the α-C atoms was computed using 460 
CPPTRAJ (63). The 3D coordinates of the structures for BcnA and BcnB subjected to the 461 
equilibration protocol described above were used for docking purposes. The two models were 462 
prepared for docking calculations by adding Kollman charges (64) with the help of 463 
AutoDockTools.  464 
 3D coordinates of norfloxacin, PmB, ceftazidime, gentamicin, Nile Red and α-tocopherol 465 
were built in Corina (65) from the SMILES code. The 3D structure of rifampicin was extracted 466 
from the crystallographic structure PDB-ID 1LSV. The structures of the seven ligands were 467 
protonated at pH 7.0 using Epik (66) and then optimized with MMFFs force field by using 468 
MacroModel version 9.9 (https://www.schrodinger.com/macromodel). Additionally, the 469 
structure of polymyxin B was subjected to 100 ps of MD simulation, at 300 K. Ligands were 470 
prepared for docking calculations using AutoDockTools by adding Gasteiger charges (67) and 471 
setting all rotatable bonds free to move during the docking calculation. 472 
 Docking calculations of all compounds were performed by means of AutoDock 4.2.2 (68). 473 
Analysis was performed with the help of AutoDockTools. The grid point spacing was set at 474 
0.375Ǻ, and a hexahedral box was built with x, y, z dimensions 21.00 Ǻ, 26.25 Ǻ, 27.75 Ǻ 475 
centred in the binding site of the protein. 200 runs using Lamarckian Genetic algorithm were 476 
performed, with a population size of 100, and 250000 energy evaluations. Side chains of residues 477 
Y85, W94 and Q41 were considered as flexible during the docking protocol. 478 
 BCN consensus motif determination. A subset of 187 curated 187 BcnA homologues from 479 
different bacterial species and families were used to obtain a consensus motif generated by the 480 
Gapped Local Alignment Motifs “GLAM2” tool (69). This motif was verified by analyzing an 481 
alignment of 1995 BCN homologues using CLUSTAL-omega and visualized using JalView. In 482 
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addition, upon submitting the predicted motif into the “GLAM2Scan” database (69) against B. 483 
cenocepacia, P. aeruginosa PAO1, M. tuberculosis H37Rv and S. aureus USA300, the correct 484 
homologues only were detected as BCNs for each of the organisms. 485 
 Statistical Analyses. Statistical analyses were conducted with GraphPad Prism 5.0. All 486 
results are shown as mean ±SEM unless otherwise stated. Unless otherwise stated, data were 487 
assumed to follow a Gaussian distribution as determined by D'Agostino-Pearson omnibus K2 488 
normality test whenever possible and hence t-tests and ANOVA were used. Unpaired t-test was 489 
used to compare the means of two unmatched groups. Paired t-test was used to compare the 490 
means of two matched groups, assuming that the distribution of the before-after differences 491 
follows a Gaussian distribution. One-way ANOVA followed by Dunn’s multiple comparison test 492 
was used to compare the means of three or more unmatched groups. The variances were not 493 
significantly different among the groups being statistically compared as determined by F-test, 494 
except in the in vivo mice infection assay (See the “Intraperitoneal infection in mice” section). 495 
The sample size (n) was chosen using GraphPad StatMate 2.0 to ensure a minimum of 80% 496 
power to detect statistically significant effects at significance level (alpha) of 0.05, two-tailed. 497 
However, the actual power of most of the assays was ≥90% and in many cases exceeded 99%. In 498 
case of MIC assays, the experiments were repeated 3 independent times and the experiment 499 
showing the lowest fold change (if applicable) was reported.  500 
 501 
SUPPLEMENTAL MATERIAL 502 
Supplemental Results 503 
Table S1.  X-ray crystallography data collection and refinement statistics 504 
Table S2.  Strains and Plasmids 505 
 23
Figure S1.  Chemical structures of antibiotics and chemicals used in this study. 506 
Figure S2. Expression and secretion profiles of BcnA and BcnB.  507 
Figure S3. Binding Assays 508 
Figure S4. BcnA and BcnB macromolecular structures and docking binding models of antibiotics 509 
into the BcnA structure. 510 
Figure S5. Nile red binding affinity of B. cenocepacia BcnA site-directed mutants 511 
Figure S6. Overall MD simulation analysis of the BcnA, BcnA D82A-D93A mutant and BcnB 512 
structures. 513 
Figure S7. Effects of B. cenocepacia BCNs on bacterial species in vitro and in vivo. 514 
 515 
 516 
ACKNOWLEDGMENTS. This work was funded by grants from Cystic Fibrosis Canada, the 517 
European Commission Marie Curie Career Integration Grant (projects 618095, NONANTIRES), 518 
and The Infection & Immunity Translational Research Group, Northern Ireland HSC to M.A.V; 519 
the Spanish Ministry for Economy and Competitiveness (MINECO, Refs.  CTQ2011-22724 and 520 
CTQ2014-57141-R), European Commission Marie Curie grants GLYCOPHARM FP7-PITN-521 
GA-2012-317297, and TOLLerant H2020-MSC-ETN-642157 to S.M.S.; and grants from the 522 
Canadian Institutes of Health Research Grant MOP-49597 and Cystic Fibrosis Canada to 523 
M.E.P.M. An Ontario Graduate Scholarship supported O.M.E. We thank Luke Alderwick, 524 
Institute of Microbiology and Infection, University of Birmingham for providing M. tuberculosis 525 
H37Rv genomic DNA, Sameer Elsayed, London Health Science Centre, for providing clinical 526 
isolates, Martin McGavin, Department of Microbiology and Immunology, the University of 527 
 24
Western Ontario for providing the S. aureus USA300 strain, and Alice Dubois, Queen's 528 
University for assistance with the mouse infection experiments. 529 
 530 
REFERENCES 531 
1. WHO. 2014. Antimicrobial resistance: Global Report on Surveillance.  World Health 532 
Organization, WHO,  533 
2. Li XZ, Plesiat P, Nikaido H. 2015. The challenge of efflux-mediated antibiotic resistance in 534 
Gram-negative bacteria. Clin Microbiol Rev 28:337-418. 535 
3. Starosta AL, Lassak J, Jung K, Wilson DN. 2014. The bacterial translation stress response. 536 
FEMS Microbiol Rev 38:1172-1201. 537 
4. Marrakchi M, Liu X, Andreescu S. 2014. Oxidative stress and antibiotic resistance in 538 
bacterial pathogens: state of the art, methodologies, and future trends. Adv Exp Med Biol 539 
806:483-498. 540 
5. Baharoglu Z, Mazel D. 2014. SOS, the formidable strategy of bacteria against aggressions. 541 
FEMS Microbiol Rev 38:1126-1145. 542 
6. de la Fuente-Nunez C, Reffuveille F, Fernandez L, Hancock RE. 2013. Bacterial biofilm 543 
development as a multicellular adaptation: antibiotic resistance and new therapeutic 544 
strategies. Curr Opin Microbiol 16:580-589. 545 
7. Poole K. 2012. Stress responses as determinants of antimicrobial resistance in Gram-546 
negative bacteria. Trends Microbiol 20:227-234. 547 
8. Levy SB, Marshall B. 2004. Antibacterial resistance worldwide: causes, challenges and 548 
responses. Nat Med 10:S122-129. 549 
9. Alekshun MN, Levy SB. 2007. Molecular mechanisms of antibacterial multidrug resistance. 550 
Cell 128:1037-1050. 551 
10. Liao YT, Kuo SC, Chiang MH, Lee YT, Sung WC, Chen YH, Chen TL, Fung CP. 2015. 552 
Acinetobacter baumannii Extracellular OXA-58 Is Primarily and Selectively Released via 553 
Outer Membrane Vesicles after Sec-Dependent Periplasmic Translocation. Antimicrob 554 
Agents Chemother 59:7346-7354. 555 
11. Lee J, Lee EY, Kim SH, Kim DK, Park KS, Kim KP, Kim YK, Roh TY, Gho YS. 2013. 556 
Staphylococcus aureus extracellular vesicles carry biologically active β-lactamase. 557 
Antimicrob Agents Chemother 57:2589-2595. 558 
 25
12. Devos S, Stremersch S, Raemdonck K, Braeckmans K, Devreese B. 2016. Intra- and 559 
Interspecies Effects of Outer Membrane Vesicles from Stenotrophomonas maltophilia on 560 
beta-Lactam Resistance. Antimicrob Agents Chemother 60:2516-2518. 561 
13. Ciofu O, Beveridge TJ, Kadurugamuwa J, Walther-Rasmussen J, Høiby N. 2000. 562 
Chromosomal β-lactamase is packaged into membrane vesicles and secreted from 563 
Pseudomonas aeruginosa. J Antimicrob Chemother 45:9-13. 564 
14. Loutet SA, Valvano MA. 2010. A decade of Burkholderia cenocepacia virulence 565 
determinant research. Infect Immun 78:4088-4100. 566 
15. Rhodes KA, Schweizer HP. 2016. Antibiotic resistance in Burkholderia species. Drug 567 
Resist Updat 28:82-90. 568 
16. El-Halfawy OM, Valvano MA. 2013. Chemical communication of antibiotic resistance by a 569 
highly resistant subpopulation of bacterial cells. PLoS One 8:e68874. 570 
17. Bishop RE. 2000. The bacterial lipocalins. Biochim Biophys Acta 1482:73-83. 571 
18. Donnarumma D, Golfieri G, Brier S, Castagnini M, Veggi D, Bottomley MJ, Delany I, 572 
Norais N. 2015. Neisseria meningitis GNA1030 is a ubiquinone-8 binding protein. FASEB J 573 
29:2260-2267. 574 
19. Handa N, Terada T, Doi-Katayama Y, Hirota H, Tame JR, Park SY, Kuramitsu S, 575 
Shirouzu M, Yokoyama S. 2005. Crystal structure of a novel polyisoprenoid-binding 576 
protein from Thermus thermophilus HB8. Protein Sci 14:1004-1010. 577 
20. Sisinni L, Cendron L, Favaro G, Zanotti G. 2010. Helicobacter pylori acidic stress 578 
response factor HP1286 is a YceI homolog with new binding specificity. FEBS J 277:1896-579 
1905. 580 
21. Benndorf D, Davidson I, Babel W. 2004. Regulation of catabolic enzymes during long-term 581 
exposure of Delftia acidovorans MC1 to chlorophenoxy herbicides. Microbiology 150:1005-582 
1014. 583 
22. Azad MA, Huang JX, Cooper MA, Roberts KD, Thompson PE, Nation RL, Li J, 584 
Velkov T. 2012. Structure-activity relationships for the binding of polymyxins with human 585 
α-1-acid glycoprotein. Biochem Pharmacol 84:278-291. 586 
23. Sahalan AZ, Dixon RA. 2008. Role of the cell envelope in the antibacterial activities of 587 
polymyxin B and polymyxin B nonapeptide against Escherichia coli. Int J Antimicrob 588 
Agents 31:224-227. 589 
24. Holm L, Rosenström P. 2010. Dali server: conservation mapping in 3D. Nucleic Acids Res 590 
38:W545-549. 591 
25. Krissinel E, Henrick K. 2007. Inference of macromolecular assemblies from crystalline 592 
state. J Mol Biol 372:774-797. 593 
 26
26. Camper N, Glasgow AM, Osbourn M, Quinn DJ, Small DM, McLean DT, Lundy FT, 594 
Elborn JS, McNally P, Ingram RJ, Weldon S, Taggart CC. 2016. A secretory leukocyte 595 
protease inhibitor variant with improved activity against lung infection. Mucosal Immunol 596 
9:669-676. 597 
27. Mak P, Zdybicka-Barabas A, Cytrynska M. 2010. A different repertoire of Galleria 598 
mellonella antimicrobial peptides in larvae challenged with bacteria and fungi. Dev Comp 599 
Immunol 34:1129-1136. 600 
28. Insua JL, Llobet E, Moranta D, Perez-Gutierrez C, Tomas A, Garmendia J, 601 
Bengoechea JA. 2013. Modeling Klebsiella pneumoniae pathogenesis by infection of the 602 
wax moth Galleria mellonella. Infect Immun 81:3552-3565. 603 
29. Flower DR, North AC, Sansom CE. 2000. The lipocalin protein family: structural and 604 
sequence overview. Biochim Biophys Acta 1482:9-24. 605 
30. Ganfornina MD, Gutierrez G, Bastiani M, Sanchez D. 2000. A phylogenetic analysis of 606 
the lipocalin protein family. Mol Biol Evol 17:114-126. 607 
31. van Opijnen T, Dedrick S, Bento J. 2016. Strain Dependent Genetic Networks for 608 
Antibiotic-Sensitivity in a Bacterial Pathogen with a Large Pan-Genome. PLoS Pathog 609 
12:e1005869. 610 
32. Mo CY, Manning SA, Roggiani M, Culyba MJ, Samuels AN, Sniegowski PD, Goulian 611 
M, Kohli RM. 2016. Systematically Altering Bacterial SOS Activity under Stress Reveals 612 
Therapeutic Strategies for Potentiating Antibiotics. mSphere 1. 613 
33. Sun K, Yajjala VK, Bauer C, Talmon GA, Fischer KJ, Kielian T, Metzger DW. 2016. 614 
Nox2-derived oxidative stress results in inefficacy of antibiotics against post-influenza S. 615 
aureus pneumonia. J Exp Med 213:1851-1864. 616 
34. Guest RL, Raivio TL. 2016. Role of the Gram-Negative Envelope Stress Response in the 617 
Presence of Antimicrobial Agents. Trends Microbiol 24:377-390. 618 
35. Poole K. 2012. Bacterial stress responses as determinants of antimicrobial resistance. J 619 
Antimicrob Chemother 67:2069-2089. 620 
36. El-Halfawy OM, Valvano MA. 2014. Putrescine reduces antibiotic-induced oxidative stress 621 
as a mechanism of modulation of antibiotic resistance in Burkholderia cenocepacia. 622 
Antimicrob Agents Chemother 58:4162-4171. 623 
37. Smirnova GV, Tyulenev AV, Muzyka NG, Peters MA, Oktyabrsky ON. 2016. 624 
Ciprofloxacin provokes SOS-dependent changes in respiration and membrane potential and 625 
causes alterations in the redox status of Escherichia coli. Res Microbiol 626 
doi:10.1016/j.resmic.2016.07.008. 627 
 27
38. Van Acker H, Gielis J, Acke M, Cools F, Cos P, Coenye T. 2016. The Role of Reactive 628 
Oxygen Species in Antibiotic-Induced Cell Death in Burkholderia cepacia Complex 629 
Bacteria. PLoS One 11:e0159837. 630 
39. Händel N, Hoeksema M, Freijo Mata M, Brul S, ter Kuile BH. 2016. Effects of Stress, 631 
Reactive Oxygen Species, and the SOS Response on De Novo Acquisition of Antibiotic 632 
Resistance in Escherichia coli. Antimicrob Agents Chemother 60:1319-1327. 633 
40. Dwyer DJ, Collins JJ, Walker GC. 2015. Unraveling the physiological complexities of 634 
antibiotic lethality. Annu Rev Pharmacol Toxicol 55:313-332. 635 
41. Boca S, Koestler F, Ksas B, Chevalier A, Leymarie J, Fekete A, Mueller MJ, Havaux 636 
M. 2014. Arabidopsis lipocalins AtCHL and AtTIL have distinct but overlapping functions 637 
essential for lipid protection and seed longevity. Plant Cell Environ 37:368-381. 638 
42. Macedo-Marquez A, Vazquez-Acevedo M, Ongay-Larios L, Miranda-Astudillo H, 639 
Hernandez-Munoz R, Gonzalez-Halphen D, Grolli S, Ramoni R. 2014. Overexpression 640 
of a monomeric form of the bovine odorant-binding protein protects Escherichia coli from 641 
chemical-induced oxidative stress. Free Radic Res 48:814-822. 642 
43. Hare NJ, Scott NE, Shin EH, Connolly AM, Larsen MR, Palmisano G, Cordwell SJ. 643 
2011. Proteomics of the oxidative stress response induced by hydrogen peroxide and 644 
paraquat reveals a novel AhpC-like protein in Pseudomonas aeruginosa. Proteomics 645 
11:3056-3069. 646 
44. Søballe B, Poole RK. 1999. Microbial ubiquinones: multiple roles in respiration, gene 647 
regulation and oxidative stress management. Microbiology 145 ( Pt 8):1817-1830. 648 
45. Nowicka B, Kruk J. 2010. Occurrence, biosynthesis and function of isoprenoid quinones. 649 
Biochim Biophys Acta 1797:1587-1605. 650 
46. Sambrook J, Fritsch EF, Maniatis T. 1990. Molecular cloning: a laboratory manual, 2nd 651 
ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York. 652 
47. Cohen SN, Chang AC, Hsu L. 1972. Nonchromosomal antibiotic resistance in bacteria: 653 
genetic transformation of Escherichia coli by R-factor DNA. Proc Natl Acad Sci U S A 654 
69:2110-2114. 655 
48. Craig FF, Coote JG, Parton R, Freer JH, Gilmour NJ. 1989. A plasmid which can be 656 
transferred between Escherichia coli and Pasteurella haemolytica by electroporation and 657 
conjugation. J Gen Microbiol 135:2885-2890. 658 
49. Figurski DH, Helinski DR. 1979. Replication of an origin-containing derivative of plasmid 659 
RK2 dependent on a plasmid function provided in trans. Proc Natl Acad Sci USA 76:1648-660 
1652. 661 
 28
50. Rosales-Reyes R, Aubert DF, Tolman JS, Amer AO, Valvano MA. 2012. Burkholderia 662 
cenocepacia type VI secretion system mediates escape of type II secreted proteins into the 663 
cytoplasm of infected macrophages. PLoS ONE 7:e41726. 664 
51. CLSI. 2012. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow 665 
Aerobically; 666 
Approved Standard—Ninth Edition. CLSI document M07-A9. Clinical and Laboratory 667 
Standards Institute, Wayne, PA.  668 
52. Harding CR, Schroeder GN, Collins JW, Frankel G. 2013. Use of Galleria mellonella as 669 
a model organism to study Legionella pneumophila infection. J Vis Exp 670 
doi:10.3791/50964:e50964. 671 
53. Grochulski P, Fodje MN, Gorin J, Labiuk SL, Berg R. 2011. Beamline 08ID-1, the prime 672 
beamline of the Canadian Macromolecular Crystallography Facility. J Synchrotron Radiat 673 
18:681-684. 674 
54. Battye TG, Kontogiannis L, Johnson O, Powell HR, Leslie AG. 2011. iMOSFLM: a new 675 
graphical interface for diffraction-image processing with MOSFLM. Acta Crystallogr D Biol 676 
Crystallogr 67:271-281. 677 
55. Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, Keegan RM, 678 
Krissinel EB, Leslie AG, McCoy A, McNicholas SJ, Murshudov GN, Pannu NS, 679 
Potterton EA, Powell HR, Read RJ, Vagin A, Wilson KS. 2011. Overview of the CCP4 680 
suite and current developments. Acta Crystallogr D Biol Crystallogr 67:235-242. 681 
56. Bunkoczi G, Echols N, McCoy AJ, Oeffner RD, Adams PD, Read RJ. 2013. 682 
Phaser.MRage: automated molecular replacement. Acta Crystallogr D Biol Crystallogr 683 
69:2276-2286. 684 
57. Terwilliger TC, Grosse-Kunstleve RW, Afonine PV, Moriarty NW, Zwart PH, Hung 685 
LW, Read RJ, Adams PD. 2008. Iterative model building, structure refinement and density 686 
modification with the PHENIX AutoBuild wizard. Acta Crystallogr D Biol Crystallogr 687 
64:61-69. 688 
58. Emsley P, Lohkamp B, Scott WG, Cowtan K. 2010. Features and development of Coot. 689 
Acta Crystallogr D Biol Crystallogr 66:486-501. 690 
59. Afonine PV, Grosse-Kunstleve RW, Echols N, Headd JJ, Moriarty NW, Mustyakimov 691 
M, Terwilliger TC, Urzhumtsev A, Zwart PH, Adams PD. 2012. Towards automated 692 
crystallographic structure refinement with phenix.refine. Acta Crystallogr D Biol Crystallogr 693 
68:352-367. 694 
60. Murshudov GN, Skubak P, Lebedev AA, Pannu NS, Steiner RA, Nicholls RA, Winn 695 
MD, Long F, Vagin AA. 2011. REFMAC5 for the refinement of macromolecular crystal 696 
structures. Acta Crystallogr D Biol Crystallogr 67:355-367. 697 
 29
61. Kobylarz MJ, Grigg JC, Takayama SJ, Rai DK, Heinrichs DE, Murphy ME. 2014. 698 
Synthesis of L-2,3-diaminopropionic acid, a siderophore and antibiotic precursor. Chem Biol 699 
21:379-388. 700 
62. Wang J, Kollman PA. 2001. Automatic parameterization of force field by systematic search 701 
and genetic algorithms. J Com Chem 22:1219-1228. 702 
63. Roe DR, CheathamIII TE. 2013. PTRAJ and CPPTRAJ: Software for Processing and 703 
Analysis of Molecular Dynamics Trajectory Data. J Chem Theory Comput 9:3084–3095. 704 
64. Besler BH, Merz KM, Kollman PA. 1990. Atomic Charges Derived from Semiempirical 705 
Methods. J Comp Chem 11:431-439. 706 
65. Sadowski J, Gasteiger J, Klebe G. 1994. Comparison of Automatic Three-Dimensional 707 
Model Builders Using 639 X-ray Structures. J Chem Inf Comput Sci 34:1000–1008. 708 
66. Greenwood JR, Calkins D, Sullivan AP, Shelley JC. 2010. Towards the comprehensive, 709 
rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in 710 
aqueous solution. J Comput Aided Mol Des 24:591-604. 711 
67. Gasteiger J, Marsili M. 1980. Iterative partial equalization of orbital electronegativity-a 712 
rapid access to atomic charges. Tetrahedron 36:3219-3228. 713 
68. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ. 714 
2009. AutoDock4 and AutoDockTools4: Automated docking with selective receptor 715 
flexibility. J Comput Chem 30:2785-2791. 716 
69. Frith MC, Saunders NF, Kobe B, Bailey TL. 2008. Discovering sequence motifs with 717 
arbitrary insertions and deletions. PLoS Comput Biol 4:e1000071. 718 
70. Zuker M. 2003. Mfold web server for nucleic acid folding and hybridization prediction. 719 
Nucleic Acids Res 31:3406-3415. 720 
 721 
722 
 30
Figure Legends 723 
 724 
FIG. 1. B. cenocepacia BcnA confers resistance to hydrophobic but not hydrophilic antibiotics. 725 
(A) MIC by broth microdilution of different antibiotics in cation-adjusted MHB at 18-24 h 726 
(representative from 3 independent experiments). (B) Luciferase expression assay of the B. 727 
cenocepacia BcnA (OME61) in response to antibiotics at 3 h. n= 6 from 2 different clones. 728 
Results are shown as percentage of relative light units RLU/OD600 relative to the control 729 
(untreated K56-2 background). The %OD600 are shown in Fig. S2D. The mean RLU/OD600 of the 730 
control is 1.3464. * p<0.05 and *** p<0.001 from unpaired two-sided Student’s t-tests compared 731 
to the respective control conditions. (C) Genomic organization of the B. cenocepacia K56 region. 732 
The asterisk denotes that the transcribed intergenic sequence between bcnA and bcnB has the 733 
potential to form strong secondary structures as determined with mFold 734 
(http://unafold.rna.albany.edu/?q=mfold/download-mfold) (70). 735 
 736 
FIG. 2. BCNs from different bacteria can restore full antibiotic resistance in B. cenocepacia 737 
∆bcnA. (A) cfu count on LB agar containing PmB, from 3 independent experiments, n=6, 738 
asterisks denote difference from ∆bcnA pSCRhaB2 mutant. * p<0.05, ** p<0.01 and *** 739 
p<0.001 determined by unpaired two-sided Student’s t-tests. (B) MIC by Etest against rifampicin 740 
(Rif), ceftazidime (Cef) and ciprofloxacin (Cipro), a representative of 3 independent 741 
experiments. The highest rifampicin concentration on the Etest strips is 32 µg/ml; ≥64 indicates 742 
that an MIC could not be detected within the Etest concentration range and would be equal to 64 743 
µg/ml or higher.  744 
 745 
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FIG. 3. BCNs bind antibiotics and other molecules hydrophobic in nature with high affinity. (A) 746 
Antibiotic assay showing reduction in concentration of hydrophobic antibiotics due to 747 
sequestration by BcnA, n=3 from three independent experiments. (B) in vitro binding assay 748 
showing binding inhibition constant (Ki) of antibiotics against 1.5 µM Nile Red binding to 1.5 749 
µM BcnA in PBS, 3 independent experiments, n=5. 750 
 751 
FIG. 4. Structural analysis of BcnA and BcnB and ligand docking modeling. (A) BcnA (blue) is 752 
a monomer. (B) BcnB (protomer 1, chain C, peach; protomer 2, chain D, grey) is a dimer. (C) 753 
Superposition of BcnA and BcnB with dissimilar tunnel opening loops boxed. (D) Docked 754 
structure of PmB in complex with the BcnA crystallographic structure. (E) Docking model 755 
presenting the superimposition of the two best predicted binding modes of Nile Red (magenta 756 
and cyan) and α-tocopherol (yellow) when docked into the BcnA crystallographic structure.  757 
 758 
FIG. 5. B. cenocepacia BcnA protects P. aeruginosa in vitro and in vivo. (A) in vitro protection 759 
of P. aeruginosa PAO1 against PmB with 1.5 µM of BcnA or BcnB, n=8 from 4 independent 760 
experiments. (B) Protection of P. aeruginosa Q502 from PmB killing in an intraperitoneal 761 
infection of C57BL/6 mice, significant difference determined by Kruskal-Wallis test. (C) The 762 
survival of G. mellonella larvae infected with P. aeruginosa PAO1 compared to control group 763 
injected with sterile PBS; 10 larvae/group; the results are obtained from 3 independent 764 
experiments. The survival of both PAO1 and PAO1-BcnB treated larvae is significantly different 765 
from that of PAO1-BcnA treated group at p= 0.0165 and 0.0303 respectively. (D) PAO1 cfu/ml 766 
recovered from larval hemolymph 200 min post-infection; n=10 from 2 independent 767 
 32
experiments. * p<0.05, ** p<0.01 and *** p<0.001 from unpaired two-sided Student’s t-tests 768 
compared to the respective control conditions.  769 
 770 
FIG. 6. Fat-soluble vitamins inhibit BCN-mediated antibiotic binding. (A) The survival of G. 771 
mellonella larvae at 20 h post-infection in an in vivo protection assay of P. aeruginosa PAO1 by 772 
1.5 µM BcnA in the presence or absence of 10 µM α-tocopherol (vitamin E) or menaquinone 773 
(vitamin K2), 10 larvae per group; the results are obtained from 4 independent experiments. * 774 
p<0.05, ** p<0.01 and *** p<0.001 from unpaired two-sided Student’s t-tests. (B) Model of the 775 
mechanism of resistance by BcnA (top) and its inhibition by the fat-soluble vitamins (bottom). 776 
 777 
 778 






	 
 
Fig. S1. Chemical structures of antibiotics and chemicals used in this study. 
 
	 
 
Fig. S2. Expression and secretion profiles of BcnA and BcnB. (A) Luciferase expression assay of BcnB and the relative 
growth of cells in the luminescence expression assay of the different B. cenocepacia BCNs in response to antibiotics at 3 h. 
Expression of BcnB (OME60). n=6 from 2 different clones. Results are shown as mean of relative light units RLU/OD600 
±SEM. (B) Growth in the expression assay of BcnB (OME60). n=6 from 2 different clones. The mean OD600 of the control 
is 0.0963. (C) Growth in the expression assay of BcnA and the associated CybB (OME61) shown in Fig. 1B.  n= 6 from 2 
different clones. Results are shown as mean of percentage of OD600 relative to the control (untreated K56-2 background) 
±SEM. The mean OD600 of the control is 0.0998. * p<0.05, ** p<0.01 and *** p<0.001 from one-way ANOVA tests of 
overall p<0.001 and Bonferroni’s post-hoc test compared to the respective untreated control conditions. (D) BcnA is the 
only secreted B. cenocepacia BCN; proteins (carrying a C-terminal FLAG-tag) were detected in whole cell lysates and 
supernatants of control untreated cultures or cultures treated with 2 µg/ml PmB by Western blot using anti-FLAG antibody. 
The α-subunit of the RNA polymerase was used as a control for cell lysis. Representative of 3 independent experiments. 
 
	 
Fig. S3. Binding Assays. (A-E) Antibiotic bioassay results showing mean antibiotic disc contents ±SEM following mixing 
with BcnA and passing through centrifugal filter units of MWCO 10 KDa compared to control antibiotic solutions. * p<0.05, 
	and ** p<0.01 from paired student’s t-tests compared to the respective control conditions. n=3 from 3 independent 
experiments. At this sample size, the actual power of the assay to detect statistically significant effects at significance level 
(alpha) of 0.05, two-tailed is >99%. (F-G) Binding displacement assays of Nile Red from 1.5 µM BcnA-1.5 µM Nile Red 
complex by antibiotics and other chemicals. 3 independent experiments, n=5. (H-M) Binding displacement isotherms 
showing the displacement of Nile Red by different antibiotics from its complex with BcnA. Mean of n=3 from a 
representative of 3 independent experiments. (N) The affinity of 1.5 µM BcnA compared to that of 1.5 µM BcnB to bind 
1.5 µM Nile Red, n=5 from 3 independent experiments. *** p<0.001 from unpaired two-sided Student’s t-test. (O) In vitro 
binding assay of 1.5 µM BcnA to Nile Red in PBS, 3 independent experiments, n=5. (P and Q) Binding isotherms from the 
fluorometric assays showing the interaction between BcnA (P) or BcnB (Q) and Nile Red. Mean of n=3 from a representative 
of 3 independent experiments. (R-T) Nile red binding affinity of BcnA to BODIPY phosphocholine (R and S) and BODIPY 
phosphoethanolamine (T), n=4 from 2 independent experiments. (U) Binding displacement assays of Nile Red from 1.5 µM 
BcnA-1.5 µM Nile Red complex by vitamins. n=5 from 3 independent experiments 
 
 
 
	 
Fig. S4. BcnA and BcnB macromolecular structures and docking binding models of antibiotics into the BcnA 
structure. BcnA (A) and BcnB (B) possess electron density within the interior of the protein cavities that was modeled as 
octaprenyl pyrophosphate (OTP; carbon, green; phosphate, brown; oxygen, red). OTP omit maps (Fo-Fc) are contoured at 
	3.0 σ and shown in black mesh. (C) The cavity opening of BcnB provides a hydrogen-bonding network to the OTP 
pyrophosphate via amino acids H42, W49, K86, and S84 through a water (red sphere) bridge. These residues are shown as 
stick figures (carbon, peach; nitrogen, blue; oxygen, red). Hydrogen bonds are represented as dotted lines with distances 
between the hydrogen bond donor and acceptor atoms shown in Å. The molar mass determination of BcnA (D) and BcnB 
(E) in solution were determined by SEC-MALS; the elution profiles (solid lines) represent the intensity of scattered light 
and are expressed as rayleigh ratios. The measured molar masses (dashed line) were constrained to the single elution peak 
for each protein. The dotted lines represent the final calculated mass for each protein. The BcnA crystallographic structure 
was used to perform molecular docking experiments. Selected docked binding modes of the antibiotics norfloxacin (F), 
rifampicin (G), ceftazidime (H), and gentamicin (I) into the BcnA structure (displayed in blue) and main residues interacting 
with the different ligands (CPK colors) are shown. 
 
 
	 
Fig. S5. Nile red binding affinity of B. cenocepacia BcnA site-directed mutants compared to the wild type, n=4, 2 
independent experiments; the smooth lines show the non-linear least square regression analysis of the binding isotherms; 
	one-way ANOVA (with overall p<0.001) Dunn's Multiple Comparison Test (A-B). (C) Consensus motif of BCN family of 
proteins. (D) Sequence alignment and consensus motif of BCN homologues used in this study. 
	
	
Fig. S6. (A-B) Overall MD simulation analysis of the BcnA, BcnA D82A-D93A mutant and BcnB structures. (A) Plot 
showing the RMSD of the position of the α-carbons of BcnA (black), BcnA D82A-D93A mutant (red) and BcnB (green) 
during the 20ns MD simulation. (B) Plot showing the RMS fluctuations of the position of all atoms during the 20ns MD 
simulation. The V38-E47 loop marked in the purple box remarks the higher flexibility observed in the case of the BcnA 
WT (black) compared to the BcnA D82A-D93A mutant (in red, lower fluctuations). 
(C-E) Superimposition of the BcnA wild type (WT, indigo) and BcnA D82A/D93A mutant (grey) minimized average 
structures from the last 5ns of MD simulation. (C) Interaction between D93/A93 and T163 respectively, along with a 
plot representing the interaction distance between the D93 carboxylate oxygen and T163 side chain OH group in the 
BcnA WT, and the A93 carbonyl oxygen and T163 side chain OH group in the BcnA D82A/D93A mutant (marked with 
black dotted lines) along the MD simulation time. (D) Hydrogen bonds (marked with black dotted lines) between the 
M42 NH group and S170 CO group, and the Q41 CO group and A173 NH group (BcnA WT in indigo, and BcnA 
D82A/D93A mutant in grey), together with the plots of the corresponding interaction distances along the MD simulation 
time. (E) Detailed views of the hydrogen bonds established between the NH groups from M84 and Y85 and the D82 
carboxylate oxygen in the BcnA WT, and the same NH groups from M84 and Y85 and the carbonyl oxygen from A82 
in the BcnA D82A/D93A mutant (marked with black dotted lines). 
	
	 
 
Fig. S7. Effects of B. cenocepacia BCNs on bacterial species in vitro and in vivo. (A) in vitro protection assays against 
PmB with 1.5 µM of BcnA or BcnB on A. baumannii AB1 (n=6 from 2 independent experiments), Salmonella typhi 
SARB63 (n=7 from 3 independent experiments), Shigella flexneri SF51571 (n=7 from 3 independent experiments), 
Acinetobacter lwoffi AB2 (n=5 from 2 independent experiments), and Acinetobacter junii AB3 (n=5 from 2 independent 
experiments). Mean ±SEM.* p<0.05, ** p<0.01 and *** p<0.001 determined by 2-way ANOVA (with overall p<0.001for 
AB1, AB2, AB3 and SF51571, p=0.001 for SARB63) and Bonferroni post-hoc tests. (B) Survival of ∆bcnA and ∆bcnB in 
Galleria mellonella larvae over a 48-h infection. 10 larvae per group; the results are obtained from 3 independent 
experiments and shown as mean of % larval survival in each experiment ±SEM. *** p<0.001 determined by 2-way ANOVA 
(with overall p<0.001) and Bonferroni post-hoc tests. At the chosen sample size (n), the actual power of the assay to detect 
statistically significant effects at significance level (alpha) of 0.05, two-tailed is 90-95%.  The right graph shows the bacterial 
recovery from hemolymph at 200 min postinfection; n=10 from 2 independent experiments shown as mean ±SEM. *** 
	p<0.001 from one-way ANOVA test (overall p<0.001) and Bonferroni’s post-hoc test. At the chosen sample size (n), the 
actual power of the assay to detect statistically significant effects at significance level (alpha) of 0.05, two-tailed is >99%.  
* p<0.05, *** p<0.001. (C) in vivo protection assay using Galleria mellonella infections. Each larva was injected with 10 
µl of suspensions of different bacteria in PBS with or without BcnA. The survival was monitored over time and compared 
to control group injected with sterile PBS. Each group included 10 larvae. Data are from 3 independent experiments. * 
p<0.05, ** p<0.01 and *** p<0.001 determined by 2-way ANOVA (with overall p<0.001) and Bonferroni post-hoc tests 
compared to the respective infection control. 
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X-ray crystallography and SEC-MALS. BCNs generally consist of an extended, eight-stranded, 
antiparallel b-barrel with a lipocalin fold, able to host lipophilic ligands inside a lipophilic tunnel, together 
with a characteristic a-helix (1). The crystal structure of BcnA was solved to 1.4 Å resolution in space 
group P61 (Table S1). The asymmetric unit contained two molecules of BcnA. Recombinant BcnA lacked 
the predicted signal peptide (first 26 amino acids) of the full-length protein. In both chains, the model 
contained N-terminal histidyl and methionyl residues encoded from the expression plasmid, residues D27 
through T185 of BcnA; only the terminal amino acid (K186) was not modeled. There are few contacts 
between the two protein chains in the asymmetric unit. The PDBePISA server (2) predicted that the 
molecules in the asymmetric unit are monomers in solution. The oligomeric solution state of BcnA was 
assessed using SEC-MALS. Recombinant BcnA, after cleavage of the 6X-His tag, has a predicted 
molecular mass of 17.4 kDa. The measured mass of BcnA in solution was 18 kDa (Fig. S4D). Based on 
these results we concluded that BcnA is a monomeric protein (Fig. 4A). Within the interior cavity of BcnA, 
continuous density was observed with a shape similar to that observed for isoprene-based molecules 
identified in homologous BCN structures (PDB IDs 1Y0G, 3Q34, 2X32, 2X34, 1WUB). We have modeled 
this density as octaprenyl pyrophosphate (OTP) (Fig. S4A) as observed in other BCN proteins after 
recombinant expression in E. coli (3, 4). Unambiguous density for the isoprene chain of OTP is observed 
in the BcnA structure; however, little density is present corresponding to the pyrophosphate portion of OTP. 
The isoprene tail of OTP makes numerous hydrophobic contacts with amino acid side chains located inside 
the BcnA barrel. The binding of these lipophilic ligands to the BCN homologues is likely due to 
recombinant expression in E. coli; hence these molecules might not be predictive of the functions of these 
BCN homologues. 
 
The crystal structure of BcnB was solved to 1.6 Å resolution in space group P21 (Table S1) with four 
molecules of BcnB in the asymmetric unit. Recombinant BcnB lacked a predicted signal peptide (first 22 
amino acids) of the full-length protein. For chains B, C, and D, residues S24 to Q192 were modeled, while 
for chain A residues A25 to Q192 were modeled. All chains lack the C-terminal amino acid (Q193). 
PDBePISA predicted a stable dimer reconstructed through crystallographic symmetry that buries ~2840 Å2 
of surface area, 15% of the solvent accessible surface area of each protomer. The mass of BcnB in solution 
was measured to be 38.1 kDa (Fig. S4E) by SEC-MALS. Recombinant BcnB, after cleavage of the 6X-His 
tag, has a predicted molecular mass of 19.2 kDa, indicating that BcnB is dimeric (Fig. 4B). Again, an 
interior of the cavity of BcnB contains continuous density that was modeled as OTP whose isoprene tail 
also makes numerous hydrophobic contacts with amino acid side chains located inside the BcnB barrel 
(Fig. S4B). In this case, the density supports both the isoprene chain and the pyrophosphate portions of 
OTP. 
 
Structural alignments by the DALI server (5) indicated that both BcnA and BcnB were most similar to E. 
coli YceI (PDB ID 1Y0G). For BcnA, 156 residues were aligned (24% sequence identity) with a root mean 
squared deviation (rmsd) of 1.5 Å. For BcnB, 165 residues were aligned (33% sequence identity) with a 
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rmsd of 1.7 Å. BcnA and BcnB also shared structural similarity (Z-score > 3.0) to eukaryotic lipocalins 
such as porcine odorant binding protein (PDB ID 1DZM) and plasma retinol-binding protein (PDB ID 
1KT6), as well as avidin (PDB ID 2A5C). These results confirm that despite low sequence identity, BcnA 
and BcnB are members of the BCN family and both possess a lipocalin fold. A structural alignment of 
BcnA and BcnB (Fig. 4C) shows that the overall folds are very similar (148 residues aligned with an rmsd 
value of 1.66 Å) despite only sharing 22% sequence identity. The largest structural differences in the 
proteins are in two of loops at the open ends of the β-barrels. In BcnB these form a longer tunnel with amino 
acid residues extending past the OTP pyrophosphate (Fig. S4B), while in BcnA the OTP pyrophosphate 
extends past the end of the protein barrel. BcnB residues H42, W49, S84 (via a water-bridge), and K86 
provide a hydrogen bonding network for the OTP pyrophosphate (Fig. S4C), while BcnA does not provide 
such a network. 
 
Extended computational studies of BcnA, BcnB, and complexes with the studied ligands. We 
conducted structure-function analyses of BcnA to propose a plausible binding mode for antibiotics. The 
stability of the BcnA and BcnB models was tested by running 20 ns of molecular dynamics (MD) 
simulations with AMBER 12 (http://ambermd.org/). RMSD deviations and RMS fluctuations (Fig. S9a-b) 
show that the two systems reach stability along the MD simulation.  
 
Docking of antibiotics in addition to Nile Red and α-tocopherol was performed in the BcnA X-Ray 
structure, and binding poses were predicted. In addition, flexibility of the protein was also taken into 
account by allowing some residues to be flexible during the docking calculations. Docking results are 
shown for BcnA in Fig. 4D-E and Fig. S4F-I. Interestingly, two distinct binding modes were predicted for 
BcnA: antibiotics were predicted to bind at the rim of the lipocalin pocket whereas more lipophylic 
molecules such as Nile Red bind deeper inside the lipophylic tunnel.  
 
All tested antibiotics shared ionic interactions with several polar residues, mainly K40, T46, D82, Q88, 
Y85, D93, and E165 (Fig. 4D and Fig. S4F-I). In addition to ionic interactions, other interactions were 
observed between the aromatic moieties present in PmB, rifampicin, norfloxacin, and ceftazidime, and 
lipophylic residues such as I171, Y85, M42, M84, V89, W94 and W166. Gentamicin does not possess any 
aromatic moieties, matching with its weak binding to BcnA. However, the inability to bind BcnA cannot 
be correlated exclusively to the absence of aromatic moieties; other factors such as entropic effects from 
solvation and/or conformational factors may be involved. 
 
Docking calculations of Nile Red and the fat-soluble α-tocopherol led to the prediction of the ligand deeply 
binding inside the lipophylic tunnel, establishing lipophylic interactions. In case of Nile Red, we predicted 
two alternative binding modes in BcnA, one with the diethylamino group pointing towards the entrance of 
the pocket, and other one with the diethylamino group pointing towards the interior of the protein. In the 
case of α-tocopherol, it was found to be mainly docked with the alkyl chain buried into the pocket and the 
cyclic head placed towards the entrance of the pocket (Fig. 4E). The OH group from the chromanol head 
was not found to establish any preferred polar interaction over the different predicted poses. 
 
BcnA model and docking calculations suggested D82 and D93 as important residues for the structure and 
function of BcnA. We found that in the wild type BcnA, the D82 carboxylate group establishes stable 
hydrogen bonds with the backbone NH groups of M84 and Y85 from helix D82-A89, and D93 carboxylate 
group establishes a stable hydrogen bond with the side chain OH group of T163. Prompted by this finding, 
we modeled the BcnA D82A-D93A mutant from the crystallographic structure, and submitted to MD 
simulations. The stability of the BcnA D82A-D93A double mutant model was tested by running 20 ns of 
MD simulation with AMBER 12. RMSD deviations and RMS fluctuations (Fig. S6A-B) show that the 
system reached stability along the MD simulation. We could only observe a slight lower fluctuation in the 
case of BcnA D82A-D93A mutant: a 3Å of RMS fluctuation is reached in the region of the V38-E47 loop 
in the case of the D82A-D93A mutant while, in the case of the WT BcnA, a 4 Å of RMS fluctuation is 
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observed for the same loop, in accordance with the B-factors extracted from the crystallography structures. 
By contrast, in the case of the MD simulation of the BcnB, the equivalent F38-R50 loop showed a 2Å of 
RMS fluctuation. To study the reason that causes this lower fluctuation in the BcnA mutant model, we 
inspected the MD simulations in detail. A higher mobility of the atoms belonging to the V38-E47 loop was 
found in the case of the wild type, as deduced from the RMS fluctuations of each residue (Fig. S6A-B). We 
observed that, in the case of the BcnA D82A-D93A mutant, the V38-E47 loop created new interactions 
between the backbone of M42 and S170, and Q41 and A173, maybe thus explaining this lower fluctuation. 
 
In the D82A-D93A mutant, the absent carboxylate group of D82 is replaced by the backbone CO group 
from A82, allowing the hydrogen bonding to NH groups from M84 and Y85. This new situation might 
affect the overall BcnA structure and, very likely, the binding of antibiotics since D82 has been identified 
by our docking calculations as an important residue for antibiotic anchorage. Furthermore, in the case of 
D93 mutation, the absence of the hydrogen bond between the carboxylate group and the T163 side chain is 
not replaced by other equivalent interaction, allowing the approach of T163-I171 loop towards the V38-
E47 loop, leading to two novel hydrogen bonds: one between the M42 NH group and the S170 CO group, 
and another one between the Q41 CO group and the A173 NH group (Fig. S6C-E). Together, this relatively 
different arrangement for the BcnA D82A-D93A mutant led to a reduced flexibility of the V38-E47 loop 
along the MD simulation time (Fig. S6C-E). The higher mobility of this V38-E47 loop could resemble the 
required movement of a similar loop in other member of the lipocalin family (the lipocalin type 
prostaglandin D synthase), where the conformational change of the Y107-S114 loop allows the change 
between the open/closed conformers (6). Nevertheless, the higher flexibility observed for the wild type 
structure could account for a better ability to bind ligands. Taking always into account the limitation of 
working with computational simulations, these observed changes might point out to a structural role for 
D82 and D93, in addition to their putative functional role in the binding of the antibiotics. To further 
investigate the role of these two residues, site-directed mutants with alanine replacements of these residues 
were prepared. D82 and to a less extent D93 were demonstrated to be important for the binding interaction 
of ligands (exemplified by Nile Red) to BcnA (Fig. S5A-B). Docking of Nile Red and α-tocopherol into 
the BcnA D82A-D93A mutant (by following the general docking protocol with the minimized average 
structure from the ns 2.5 to the ns 5 of the MD simulation) did not lead to any binding pose inside the 
lipophilic tunnel. This agrees with the experimental results obtained with the BcnA D82A-D93A mutant 
protein. 
 
Since BCNs are highly conserved among bacteria sharing the characteristic lipocalin tertiary structure, we 
determined the consensus motif of this protein family (Fig. S5C) (7).The D93 residue of BcnA of B. 
cenocepacia was highly conserved. Aspartate residues at distance from D93 comparable to the distance to 
D82 in B. cenocepacia BcnA were found in the motif (7). Together, this suggests that D82 and D93 may 
have a structural role to maintain the 3D structure and the opening of the lipophilic tunnel of BcnA, and 
also they may be proposed as key residues to interact with antibiotics, thus playing an essential role in the 
resistance mechanism mediated through BCNs. This mode of interaction between BCN and antibiotics 
could be common among this large family of conserved bacterial proteins. 
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	Table S1. X-ray crystallography data collection and refinement statistics 
Parameter BcnA BcnB 
Data Collection*   
   Resolution Range (Å) 35.9 - 1.4 (1.43 – 1.4) 37.3 - 1.6 (1.63 – 1.6) 
   Space Group P61 P21 
   Unit cell dimension (Å) a = 93.97, b = 93.97, c = 76.66, γ = 
120o 
a = 51.2, b = 101.2, c = 63.5, β = 
97.2o 
   Unique Reflections 75,559 (4,004) 82,019 (3,495) 
   Completeness (%) 99.9 (99.4) 97.3 (78.7) 
   CC1/2 0.999 (0.829) 0.997 (0.892) 
   Average I/σI 17.1 (3.0) 11.3 (3.3) 
   Redundancy 10.5 (5.7) 3.8 (3.1) 
   Rmerge 0.061 (0.492) 0.056 (0.265) 
Refinement   
   Rwork (Rfree) 0.156 (0.183) 0.158 (0.192) 
   Number of water 
molecules 
274 482 
   Overall B-factor (Å2) 28.4 17.1 
   r.m.s.d.   
      Bond lengths (Å) 0.01 0.025 
      Bond angles (o) 1.46 2.44 
   Ramachandran Plot (%)   
      In most favorable 96.0 96.9 
      In disallowed 0.3 0.8 
*Data collection statistics in parentheses represent the highest resolution shells. Coordinates for the X-ray 
crystal structures of BcnA and BcnB have been deposited to the Protein Data Bank with Accession Codes 
5IXH and 5IXG, respectively. 
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Table S2. Strains and Plasmids 
Strain or plasmid Relevant characteristicsa Source 
and/or 
reference 
Strains 
Burkholderia cenocepacia 
K56-2 ET12 clone related to J2315, CF clinical Isolate bBCRRC, (1) 
OME19 K56-2 pSCrhaB2; TpR (2) 
OME37 K56-2 pOE12; BCAL3310 with C-terminus FLAG tag; TetR This study 
OME40 K56-2 pOE13; BCAL3311 with C-terminus FLAG tag; TetR This study 
   
OME60 K56-2, PBCAL3310::pGSVTp-luxCDABE; TpR This study 
OME61 K56-2, PBCAL3312-3311::pGSVTp-luxCDABE; TpR This study 
OME62 K56-2, ∆BCAL3311 This study 
   
OME65 K56-2, ∆BCAL3310 This study 
OME66 K56-2 pDA17; TetR This study 
OME71 OME62 pSCrhaB2; TpR This study 
OME72 OME62 pOE33 (BCAL3311); TpR This study 
OME73 OME62 pOE34 (PA0423); TpR This study 
OME74 OME62 pOE35 (PA4340); TpR This study 
OME75 OME62 pOE36 (PA4345); TpR This study 
OME76 OME62 pOE37 (Rv1890c); TpR This study 
OME77 OME62 pOE38 (SAUSA300_2620); TpR This study 
 
Escherichia coli 
DH5α F-f80lacZ M15 endA1 recA1 supE44 hsdR17(rK- mK+)deoR thi-1  
nupG supE44 gyrA96relA1 ∆(lacZYA-argF)U169, λ– 
Laboratory 
stock 
GT115 F– mcrA∆(mrr-hsdRMS-mcrBC) f80∆lacZ∆M15 ∆lacX74 recA1 
rpsL (StrA) endA1∆dcm uidA(∆MluI)::pir-116 ∆sbcC-sbcD 
Invivogen, 
San Diego, 
CA 
BL21 F−dcm ompT hsdS(rB−mB−) gal  Novagen 
 
Pseudomonas aeruginosa 
PAO1 Non‐CF clinical isolate (3) 
Q502 CF clinical isolate  (4) 
 
Salmonella typhi 
SARB63  (5) 
 
Shigella flexneri 
SF51571 Serotype 1a, antigenic formula 1:4 Laboratory 
stock 
 
Acinetobacter species 
A. baumannii 
(AB1) 
Clinical isolate LHSCc 
A. lwoffi (AB2) Clinical isolate LHSCc 
A. junii (AB3) Clinical isolate LHSCc 
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Klebsiella pneumoniae 
Kpn18 Clinical isolate Laboratory 
stock 
 
Staphylococcus aureus 
USA300 Community acquired MRSA Martin 
McGavin 
   
Plasmids 
pRK2013 oricolE1, RK2 derivative, KanR, mob+, tra+ (6) 
pGSVTp-lux Mobilizable suicide vector containing lux operon, derivative  
from pGSV3-lux(7); OriT; TpR 
(8) 
pSCrhaB2 oripBBR1rhaR, rhaS, PrhaBTpRmob+ (9) 
pDAI-SceI-SacB oripBBR1, TetR, Pdhfr, mob+, expressing I-SceI, SacB (10) 
pGPI-SceI oriR6K,  ΩTpR , mob+, including an I-SceI  
restriction site 
(11) 
pDA17 oripBBR1, TetR, mob+, Pdhfr, FLAG epitope 
 
D. Aubert, 
unpublished 
pOE12 pDA17, BCAL3310, C-terminus FLAG, TetR This study 
pOE13 pDA17, BCAL3311, C-terminus FLAG, TetR This study 
pOE15 BCAL3310 without signal peptide encoding sequence cloned in 
pET28a(+) 
(2) 
pOE16 BCAL3311 without signal peptide encoding sequence cloned in 
pET28a(+) 
(2) 
pOE22 PBCAL3310::luxCDABE transcriptional fusion in pGSVTp-lux, TpR This study 
pOE23 PBCAL3312-3311::luxCDABE transcriptional fusion in pGSVTp-lux,  
TpR 
This study 
pOE25 pGPI-SceI with fragments flanking BCAL3310, TpR This study 
pOE26 pGPI-SceI with fragments flanking BCAL3311, TpR This study 
   
pOE33 pSCrhaB2, BCAL3311, TpR This study 
pOE34 pSCrhaB2, PA0423, TpR This study 
pOE35 pSCrhaB2, PA4340, TpR This study 
pOE36 pSCrhaB2, PA4345, TpR This study 
pOE37 pSCrhaB2, Rv1890c, TpR This study 
pOE38 pSCrhaB2, SAUSA300_2620, TpR This study 
pOE39 pOE16, D82A This study 
pOE41 pOE16, D93A This study 
pOE46 pOE39, D93A This study 
aTpR, trimethoprim resistance, KanR, kanamycin resistance, TetR, tetracycline resistance. 
bBCRRC, B. cepacia Research and Referral Repository for Canadian CF Clinics. 
cLHSC, London Health Science Centre, London, Ontario, Canada. 
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